Thymulin vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Thymulin
Thymulin (Facteur Thymique Sérique) is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells. It plays important roles in T-cell differentiation and immune system maturation.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | Thymulin | Cagrilintide |
|---|---|---|
| Mechanism | Requires zinc for biological activity. Promotes T-cell differentiation, modulates cytokine production, and influences neuroendocrine function. Levels decline significantly with age. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Research protocols vary. Often studied alongside zinc supplementation. Typical research doses in the microgram range. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Subcutaneous or intramuscular injection in research settings. Requires adequate zinc status for activity. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Limited data on exogenous administration. Theoretical effects on immune function require monitoring. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |